DESIDERIO FAVARATO

(Fonte: Lattes)
Índice h a partir de 2011
15
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico

Resultados de Busca

Agora exibindo 1 - 5 de 5
  • conferenceObject
    CHARACTERIZATION, TREATMENT AND OUTCOMES OF PATIENTS WITH STABLE ISCHEMIC HEART DISEASE IN A TERTIARY-CARE CENTER IN BRAZIL
    (2020) MOREIRA, Eduardo; GARZILLO, Cibele; AYRES, Sandra; FAVARATO, Desiderio; PITTA, Fabio; LIMA, Eduardo Gomes; HUEB, Whady; SERRANO, Carlos
  • conferenceObject
    Gender-related Differences in the Management of Chronic Coronary Syndrome: Registry Data of a Tertiary Center in Brazil
    (2020) SERRANO, Carlos V.; MOREIRA, Eduardo M.; GARZILLO, Cibele L.; MONTENEGRO, Luiz M.; TABUSE, Cindy L.; KORMANN-MOREIRA, Mylena C.; SEGRE, Alexandre W.; BOLTA, Paula M.; FAVARATO, Desiderio; PITTA, Fabio G.; LIMA, Eduardo G.; REZENDE, Paulo H.; HUEB, Whady A.
  • conferenceObject
    Neither Moderate Consumption of Sugarcane Liquor (""Cachaca"") Nor of Red Wine Affect Cardiovascular Risk Biomarkers in Healthy Individuals
    (2020) CELLIA, Pedro H.; LIMA, Eduardo G.; MOREIRA, Eduardo; BARBOSA, Livia B.; PITTA, Fabio G.; RACHED, Fabiana H.; STRUNZ, Celia M.; FAVARATO, Desiderio; GARZILLO, Cibele L.; SERRANO, Carlos V.
  • article 14 Citação(ões) na Scopus
    Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial
    (2020) LIMA, Eduardo Gomes; CHARYTAN, David M.; HUEB, Whady; AZEVEDO, Diogo Freitas Cardoso de; GARZILLO, Cibele Larrosa; FAVARATO, Desiderio; LINHARES FILHO, Jaime Paula Pessoa; MARTINS, Eduardo Bello; BATISTA, Daniel Valente; REZENDE, Paulo Cury; HUEB, Alexandre Ciappina; RAMIRES, Jose Antonio Franchini; KALIL FILHO, Roberto
    Background. Chronic kidney disease (CKD) is associated with a worse prognosis in patients with stable coronary artery disease (CAD); however, there is limited randomized data on long-term outcomes of CAD therapies in these patients. We evaluated long-term outcomes of CKD patients with CAD who underwent randomized therapy with medical treatment (MT) alone, percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). Methods. Baseline estimated glomerular filtration rate (eGFR) was obtained in 611 patients randomized to one of three therapeutic strategies in the Medicine, Angioplasty, or Surgery Study II trial. Patients were categorized in preserved renal function and mild or moderate CKD groups depending on their eGFR (>= 90, 89-60 and 59-30 mL/min/1.73 m(2), respectively). The primary clinical endpoint, a composite of overall death and myocardial infarction, and its individual components were analyzed using proportional hazards regression (Clinical Trial registration information: http://www.controlled-trials.com.Registration number: ISRCTN66068876). Results. Of 611 patients, 112 (18%) had preserved eGFR, 349 (57%) mild dysfunction and 150 (25%) moderate dysfunction. The primary endpoint occurred in 29.5, 32.4 and 44.7% (P = 0.02) for preserved eGFR, mild CKD and moderate CKD, respectively. Overall mortality incidence was 18.7, 23.8 and 39.3% for preserved eGFR, mild CKD and moderate CKD, respectively (P = 0.001). For preserved eGFR, there was no significant difference in outcomes between therapies. For mild CKD, the primary event rate was 29.4% for PCI, 29.1% for CABG and 41.1% for MT (P = 0.006) [adjusted hazard ratio (HR) = 0.26, 95% confidence interval (CI) 0.07-0.88; P = 0.03 for PCI versus MT; and adjusted HR = 0.48; 95% CI 0.31-0.76; P = 0.002 for CABG versus MT]. We also observed higher mortality rates in the MT group (28.6%) compared with PCI (24.1%) and CABG (19.0%) groups (P = 0.015) among mild CKD subjects (adjusted HR = 0.44, 95% CI 0.25-0.76; P = 0.003 for CABG versus MT; adjusted HR = 0.56, 95% CI 0.07-4.28; P = 0.58 for PCI versus MT). Results were similar with moderate CKD group but did not achieve significance. Conclusions. Coronary interventional therapy, both PCI and CABG, is associated with lower rates of events compared with MT in mild CKD patients >10 years of follow-up. More study is needed to confirm these benefits in moderate CKD.